世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000037083

非ホジキンリンパ腫治療薬市場-規模、シェア、動向分析レポート、予測2023-2030

Grand View Research Inc.

Non Hodgkin Lymphoma Therapeutics Market Size, Share & Trends Analysis Report, And Segment Forecasts, 2023 - 2030

発刊日 2023/12

言語英語

体裁PDF/149ページ

ライセンス/価格149ページ

0000037083

Individual
Team
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

非ホジキンリンパ腫治療薬の市場規模、シェア、動向分析レポート:治療タイプ別(放射線療法、化学療法、標的療法)、細胞タイプ別、地域別、およびセグメント予測、2023-2030

市場規模と動向

非ホジキンリンパ腫治療薬の世界市場の規模は、2022年に91億4,000万ドルと評価され、2023年から2030年にかけて7.95%のCAGRで成長すると予想されます。非ホジキンリンパ腫治療薬市場は、非ホジキンリンパ腫疾患のより効果的な治療法を提供することを目的とした斬新で革新的な開発件数の増加により、大幅な成長を遂げると予想されます。がん患者の増加が続いているため、効果的な治療法の必要性が高まっています。米国がん協会によると、2023年1月時点で、NHLを発症する生涯リスクは、男性で43人に1人、女性で53人に1人でした。

レポート詳細

目次

Table of Contents

Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 GVR’s internal database
1.2 Research Methodology
1.3 Geographic scope & assumptions
1.4 Region-wise market calculation
1.4.1 Region-wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.5 Region-based segment share calculation
1.6 List of Secondary Sources

Chapter 2 Executive Summary
2.1 Market Snapshot

Chapter 3 Hematologic Malignancies Market Variables, Trends & Scope
3.1 Market segmentation& scope
3.2 Market Driver Analysis
3.2.1 Growing Incidence of blood cancer
3.2.2 Increasing investment for cancer research
3.2.3 Strong product pipeline
3.2.4 Increasing Acquisition and Collaboration
3.3 Market restraint analysis
3.3.1 Reimbursement Policies
3.3.2 Large Capital Investment
3.4 Penetration & growth prospect mapping
3.5 Hematologic malignancies - SWOT Analysis, By Factor (political & legal, economic and technological)
3.6 Industry Analysis - Porter’s

Chapter 4 Hematologic Malignancies Market: Type Outlook
4.1 Hematologic malignancies market by type, movement analysis
4.2 Leukemia
・ Leukemia Market estimates and forecast, 2014 - 2025 (USD Billion)
4.2.1 Acute lymphocytic Leukemia
・ Acute lymphocytic Leukemia Market estimates and forecast, 2014 - 2025 (USD Billion)
4.2.2 Chronic lymphocytic Leukemia
・ Chronic lymphocytic Leukemia Market estimates and forecast, 2014 - 2025 (USD Billion)
4.2.3 Acute myeloid Leukemia
・ Acute myeloid Leukemia Market estimates and forecast, 2014 - 2025 (USD Billion)
4.2.4 Chronic myeloid Leukemia
・ Chronic myeloid Leukemia Market estimates and forecast, 2014 - 2025 (USD Billion)
4.3 Lymphoma
・ Lymphoma Market estimates and forecast, 2014 - 2025 (USD Billion)
4.4 Multiple Myeloma
・ Multiple myeloma Market estimates and forecast, 2014 - 2025 (USD Billion)
4.5 Others
・ Others Market estimates and forecast, 2014 - 2025 (USD Billion)

Chapter 5 Hematologic Malignancies Market: Therapy Estimates & Trend Analysis
5.1 Hematologic malignancies market: Therapy movement analysis
5.2 Chemotherapy
・ Chemotherapy market estimates and forecast, 2014 - 2025 (USD Billion)
5.3 Radiotherapy
・ Radiotherapy market estimates and forecast, 2013 - 2024 (USD Billion)
5.4 Immunotherapy
・ Immunotherapy market estimates and forecast, 2014 - 2025 (USD Billion)
5.5 Stem cell transplantation
・ Stem cell transplantation market estimates and forecast, 2014 - 2025 (USD Billion)
5.6 Others
・ Others market estimates and forecast, 2014 - 2025 (USD Billion)

Chapter 6 Hematologic Malignancies Market: Regional Outlook
6.1 Hematologic malignancies market share by region, 2015 & 2025 (USD Billion)
6.2 North America
6.2.1 U.S
6.2.1.1 U.S. hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.2.1.2 U.S. hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.2.2 Canada
6.2.2.1 Canada hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.2.2.2 Canada hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.3 Europe
6.3.1 UK
6.3.1.1 UK hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.3.1.2 UK hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.3.2 Germany
6.3.2.1 Germany hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.3.2.2 Germany hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.4 Asia Pacific
6.4.1 Japan
6.4.1.1 Japan hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.4.1.2 Japan hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.4.2 China
6.4.2.1 China hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.4.2.2 China hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.4.3 India
6.4.3.1 India hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.4.3.2 India hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.5 Latin America
6.5.1 Brazil
6.5.1.1 Brazil hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.5.1.2 Brazil hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.5.2 Mexico
6.5.2.1 Mexico hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.5.2.2 Mexico hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)
6.6 MEA
6.6.1 South Africa
6.6.1.1 South Africa hematologic malignancies market, by type, 2014 - 2025 (USD Billion)
6.6.1.2 South Africa hematologic malignancies market, by therapy, 2014 - 2025 (USD Billion)

Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Market Participation Categorization
7.2.1 Company Profiles
7.2.2 Pfizer Inc
・ Company overview
・ Financial performance
・ Product benchmarking
・ Strategic initiatives
7.2.3 F. Hoffmann-LA Roche Ltd
・ Company overview
・ Financial Performance
・ Product benchmarking
・ Strategic initiatives
7.2.4 Sanofi
・ Company overview
・ Financial performance
・ Product benchmarking
・ Strategic initiatives
7.2.5 Bristol-Myers Squibb Company
・ Company overview
・ Financial performance
・ Product benchmarking
・ Strategic initiatives
7.2.6 AbbVie Inc
・ Company overview
・ Financial performance
・ Product benchmarking
・ Strategic initiatives
7.2.7 Novartis AG
・ Company overview
・ Financial performance
・ Product benchmarking
・ Strategic initiatives
7.2.8 GlaxoSmithKline PLC
・ Company overview
・ Financial performance
・ Product benchmarking
・ Strategic initiatives
7.2.9 Celgene Corporation
・ Company overview
・ Financial performance
・ Product benchmarking
・ Strategic initiatives
7.2.10 Johnson & Johnson Services, Inc
・ Company overview
・ Financial performance
・ Product benchmarking
・ Strategic Initiatives
7.2.11 Takeda Pharmaceutical Company
・ Company overview
・ Financial performance
・ Product benchmarking
・ Strategic Initiatives

List of Tables
TABLE 1 Country share estimation
TABLE 2 North America hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 3 North America hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 4 North America hematologic malignancies market estimates and forecasts, by Therapy, 2014 - 2025 (USD Billion)
TABLE 5 U.S. hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 6 U.S. hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 7 U.S. hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 8 Canada hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 9 Canada hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 10 Canada hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 11 Europe hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 12 Europe hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 13 Europe hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 14 U.K hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 15 U.K hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 16 U.K hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 17 Germany hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 18 Germany hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 19 Germany hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 20 Asia Pacific hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 21 Asia Pacific hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 22 Asia Pacific hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 23 Japan hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 24 Japan hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 25 Japan hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 26 China hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 27 China hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 28 China hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 29 India hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 30 India hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 31 India hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 32 Latin America hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 33 Latin America hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 34 Latin America hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 35 Brazil hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 36 Brazil hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 37 Brazil hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 38 Mexico hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 39 Mexico hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 40 Mexico hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 41 MEA hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 42 MEA hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 43 MEA hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)
TABLE 44 South Africa hematologic malignancies market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
TABLE 45 South Africa hematologic malignancies market estimates and forecasts, by leukemia, 2014 - 2025 (USD Billion)
TABLE 46 South Africa hematologic malignancies market estimates and forecasts, by therapy, 2014 - 2025 (USD Billion)

List of Figures
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Value chain based sizing & forecasting
FIG. 4 QFD modeling for market share assessment
FIG. 5 Market summary
FIG. 6 Market trends &outlook
FIG. 7 Market segmentation & scope
FIG. 8 Market driver relevance analysis (Current & future impact)
FIG. 9 Estimated New Cases of Blood Cancer in U.S. (2017)
FIG. 10 Acquisitions and Collaborations according to Therapeutic area
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 National Reimbursement Status
FIG. 13 Penetration & growth prospect mapping
FIG. 14 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 15 Porter’s Five Forces Analysis
FIG. 16 Hematologic malignancies market type outlook
FIG. 17 Hematologic malignancies market: Type movement analysis
FIG. 18 Global Leukemia market, 2014 - 2025 (USD Billion)
FIG. 19 Global Acute lymphocytic leukemia market, 2014 - 2025 (USD Billion)
FIG. 20 Global Chronic lymphocytic leukemia market, 2014 - 2025 (USD Billion)
FIG. 21 Global Acute myeloid leukemia market, 2014 - 2025 (USD Billion)
FIG. 22 Global Chronic myeloid leukemia market, 2014 - 2025 (USD Billion)
FIG. 23 Global Lymphoma market, 2014 - 2025 (USD Billion)
FIG. 24 Global Multiple myeloma market, 2014 - 2025 (USD Billion)
FIG. 25 Global Others market, 2014 - 2025 (USD Billion)
FIG. 26 Hematologic malignancies market therapy outlook key takeaways
FIG. 27 Hematologic malignancies market: Leukemia movement analysis
FIG. 28 Global Chemotherapy market, 2014 - 2025 (USD Billion)
FIG. 29 Global Radiotherapy market, 2014 - 2025 (USD Billion)
FIG. 30 Global Immunotherapy market, 2014 - 2025 (USD Billion)
FIG. 31 Global Stem cell transplantation market, 2014 - 2025 (USD Billion)
FIG. 32 Global others market, 2014 - 2025 (USD Billion)
FIG. 33 Regional market place: Key takeaways
FIG. 34 Regional outlook, 2015 & 2025
FIG. 35 North America hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 36 U.S. hematologic malignancies market, 2013 - 2024 (USD Billion)
FIG. 37 Canada hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 38 Europe hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 39 UK hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 40 Germany hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 41 Asia Pacific hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 42 Japan hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 43 China hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 44 India hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 45 Latin America hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 46 Brazil hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 47 Mexico hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 48 MEA hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 49 South Africa hematologic malignancies market, 2014 - 2025 (USD Billion)
FIG. 50 Strategy framework
FIG. 51 Participant categorization

この商品のレポートナンバー

0000037083

TOP